Endometrosis
Endometriosis
Endometriosis is a disabling disease affecting nearly one in ten women characterized by the uncontrolled development of endometrium tissues outside the uterus. The disease is associated with chronic pain and fertility issues. Available therapeutic options are limited to symptomatic treatment to alleviate pain or surgery, urging health and political authorities to declare endometriosis as “National Health Cause” such as in France in 2022
A number of publications showed the expression of netrin-1 in endometriosis lesions and the role of the Epithelial-to-Mesenchymal Transition (EMT) appears to be an important factor event in the progression of the disease.
Based on this strong scientific rationale and given the lack of therapeutic options for women suffering from this debilitating disease, NETRIS Pharma decided to launch a development program aimed at delivering the first non-hormonal disease modifying treatment in endometriosis with a monoclonal antibody developed by NETRIS Pharma targeting netrin-1.
This project is supported by a 3.9 M€ grant from BPI.
